Table 4.

Correlation of HDAC mRNA expression with overall survival in different clinical stage ovarian cancer patients.

HDAC	Clinical stage	cases	HR (95% CI)	P value
HDAC1	I+II	135	2.71(1.02-7.19)	0.0376*
	III+IV	1220	1.34(1.12-1.59)	0.001*
HDAC2	I+II	83	0.3(0.11-0.83)	0.0142*
	III+IV	487	1.36(1.08-1.7)	0.0084*
HDAC4	I+II	83	0.69(0.25-1.92)	0.479
	III+IV	487	1.17(0.93-1.47)	0.1789
HDAC5	I+II	83	0.36(0.13-0.99)	0.0395*
	III+IV	487	1.12(0.9-1.41)	0.3114
HDAC11	I+II	83	3.8(0.86-16.83)	0.059
	III+IV	487	1.27(1.01-1.59)	0.0406*

*: P<0.05